comparemela.com

Latest Breaking News On - Burst edition - Page 1 : comparemela.com

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.